



Divisione di Guna S.p.a.

ABSTRACT da Der Hautarzt (2015)

Prof. Torello Lotti

**Specializzazione in Dermatologia - Full Professor & Chair of Dermatology and Venereology Chair,
Executive Scientific Committee Vitiligo Research Foundation, New York, NY, USA**

PSORIASI: EFFICACIA DEL TRATTAMENTO DELLA PSORIASI CON FOTOTERAPIA E CITOCHINE A BASSO DOSAGGIO

Generale

La psoriasi è una malattia infiammatoria cronica autoimmune della pelle che colpisce 1-3% della popolazione mondiale. La maggior parte dei pazienti affetti da psoriasi hanno psoriasi a placche, o psoriasi volgare, caratterizzati da ispessite placche eritematose squamose e appare in una varietà di forme con caratteristiche distinte. La psoriasi è associata a una riduzione della qualità della vita e a gravi comorbidità.

Obiettivo

Scopo di questo studio clinico retrospettivo osservazionale spontaneo è stato quello di valutare l'attività farmacologica di un trattamento avanzato basato sull'uso di UVA-1 laser terapia in associazione o senza la somministrazione di citochine a basso dosaggio (interleuchina 4, Interleuchina 10 e anticorpi anti-IL -1) in pazienti affetti da psoriasi vulgaris.

Conclusione

In questo studio è stata valutata l'efficacia della UVA-1 phototherapy e, in parallelo, l'aumento di efficacia della medesima terapia quando associata alla somministrazione di basse dosi di citochine nel miglioramento del punteggio PASI.

Questi risultati dimostrano l'efficacia dell'uso combinato di fototerapia e terapia con citochine a basso dosaggio attivate, evidenziando il ruolo fondamentale delle citochine anti-infiammatorie (IL-4, IL-10, anticorpi anti-IL-1) nel trattamento della psoriasi volgare.

Ulteriori studi sono necessari per confermare questi dati preliminari.



Divisione di Guna S.p.a.

Bibliografia

1. Lee SH, Jeong SK, Ahn SK (2006) An update of the defensive barrier function of skin. *Yonsei Med J* 47(3):293–306.
2. Ramos-e-Silva M, Jacques C (2012) Epidermal barrier function and systemic diseases. *Clin Dermatol* 30(3):277–279.
3. Proksch E, Brandner JM, Jensen JM (2008) The skin: an indispensable barrier. *Exp Dermatol* 17(12):1063–1072.
4. Streilein JW (1983) Skin-associated lymphoid tissues (SALT): origins and functions. *J Invest Dermatol* 80(Suppl):12s–16s.
5. Tay SS, Roediger B, Tong PL et al (2013) The skin-resident immune network. *Curr Dermatol Rep* 3:13–22.
6. Ono S, Kabashima K (2015) Proposal of inducible skin-associated lymphoid tissue (iSALT). *Exp Dermatol* 24(8):630–631.
7. Stalder JF, Tennstedt D, Deleuran M et al (2014) Fragility of epidermis and its consequence in dermatology. *J Eur Acad Dermatol Venereol* 28(Suppl 4):1–18.
8. Zenz R, Eferl R, Kenner L et al (2005) Psoriasislike skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. *Nature* 437(7057):369–375.
9. Lowes MA, Suárez-Fariñas M, Krueger JG (2014) Immunology of psoriasis. *Annu Rev Immunol* 32:227–255.
10. Grozdev I, Korman N, Tsankov N (2014) Psoriasis as a systemic disease. *Clin Dermatol* 32(3):343–350.
11. Torres T, Bettencourt N (2014) Psoriasis: the visible killer. *Rev Port Cardiol* 33(2):95–99.
12. Palfreeman AC, McNamee KE, McCann FE (2013) New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. *Drug Des Devel Ther* 7:201–210.
13. Chiricozzi A, Suárez-Fariñas M, Fuentes-Duculan J et al (2015) Increased expression of IL-17 pathway genes in non-lesional skin of moderate-to-severe psoriasis vulgaris. *Br J Dermatol*. doi:10.1111/bjd.14034. (Epub ahead of print).
14. Stawczyk-Macieja M, Szczerkowska-Dobosz A, Rębała K et al (2015) Genetic background of skin barrier dysfunction in the pathogenesis of psoriasis vulgaris. *Postepy Dermatol Alergol* 32(2):123–126.
15. Harden JL, Krueger JG, Bowcock AM (2015) The immunogenetics of psoriasis: a comprehensive review. *J Autoimmun*. doi:10.1016/j.jaut.2015.07.008. (Epub ahead of print).
16. Li N, Yamasaki K, Saito R et al (2014) Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36 γ induction in human epidermal keratinocytes. *J Immunol* 193(10):5140–5148.
17. Seledtsov VI, Seledtsova GV (2012) A balance between tissue-destructive and tissue-protective immunities: a role of toll-like receptors in regulation of adaptive immunity. *Immunobiology* 217(4):430–435.
18. Martin G, Guérard S, Fortin MM et al (2012) Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact. *Lab Invest* 92(7):1058–1070.
19. Iwakura Y, Ishigame H (2006) The IL-23/IL-17 axis in inflammation. *J Clin Invest* 116(5):1218–1222.
20. Yu N, Liu S, Yi X et al (2015) Serum amyloid A induces interleukin-1 β secretion from keratinocytes via the NACHT, LRR and PYD domains-containing protein 3 inflammasome. *Clin Exp Immunol* 179(2):344–353.
21. Choi MR, Choi DK, Sohn KC et al (2015) Inhibitory effect of *Paeonia lactiflora* Pallas extract (PE) on poly (I:C)-induced immune response of epidermal keratinocytes. *Int J Clin Exp Pathol* 8(5):5236–5241.
22. Cooper KD, Hammerberg C, Baadsgaard O et al (1990) Interleukin-1 in human skin: dysregulation in psoriasis. *J Invest Dermatol* 95(5 Suppl):24S–26S.
23. Garg T, Rath G, Goyal AK (2014) Ancient and advanced approaches for the treatment of an inflammatory autoimmune disease-psoriasis. *Crit Rev Ther Drug Carrier Syst* 31(4):331–364.
24. Fernandez A (2015) Dermatology update: the dawn of targeted treatment. *Cleve Clin J Med* 82(5):309–320.
25. Zerbini N, Portale S, Palmieri B et al (2012) A preliminary study to assess the efficacy of a new UVA1 laser for treatment of psoriasis. *Photomed Laser Surg* 30(10):610–614.



Divisione di Guna S.p.a.

26. Nisticò SP, Saraceno R, Chiricozzi A et al (2013) UVA-1 laser in the treatment of palmoplantar pustular psoriasis. *Photomed Laser Surg* 31(9):434–438.
27. D’Erme AM, Mateeva V, Lotti T (2015) UVA-1 laser: new device in phototherapeutic armamentarium of the dermatologist. *Dermatol Ther*. doi:10.1111/dth.12245. (Epub ahead of print).
28. Gariboldi S, Palazzo M, Zanobbio L et al (2009) Low dose oral administration of cytokines for treatment of allergic asthma. *Pulm Pharmacol Ther* 22(6):497–510.
29. D’Amico L, Ruffini E, Ferracini R et al (2012) Low Dose of IL-12 stimulates T cell response in cultures of PBMCs derived from non small cell lung cancer patients. *J Cancer Ther* 3:337–342.
30. Cardani D, Dusio GF, Luchini P et al (2013) Oral administration of interleukin-10 and anti-IL-1 antibody ameliorates experimental intestinal inflammation. *Gastroenterol Res* 6(4):124–133.
31. Radice E, Miranda V, Bellone G (2014) Low-doses of sequential-kinetic-activated interferon-gamma enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with earlystage colorectal cancer. A preliminary study. *Intern Immunopharm* 19(1):66–73.
32. Roberti ML, Ricottini L, Capponi A et al (2014) Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris. *J Biol Regul Homeost Agents* 28(1):133–139.
33. Luchetti P (2014) Increasing of visual function in patients with retinal atrophy treated with drugs of Low Dose Medicine. Monocentric retrospective observational study. *Minerva Oftalmologica* 56(3–4):53–61.
34. Barygina V, Becatti M, Lotti T et al (2015) Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin. *J Dermatol Sci* 79(2):163–170.
35. Lotti T, Hercogova J, Wollina U et al (2015) Vitiligo: successful combination treatment based on oral low dose cytokines and different topical treatments. *J Biol Regul Homeost Agents* 29(1 Suppl):53–58.